-
US futures point to an over 1% bearish gap at session open
-
Gilead (GILD.US) set to surge another 5% at the open
-
Microsoft (MSFT.US) issued sales warning on coronavirus
While US indices finished yesterday’s session with just moderate declines, S&P 500 futures slumped overnight on news of the first confirmed US virus case of unknown origin. To make things worse, the New York Times reported that the patient was not immediately tested for the virus as he did not meet criteria set by Centre for Disease Control to qualify even for testing. S&P 500, Nasdaq, Dow Jones and Russell 2000 are all expected to open over 1% lower today.
Sell-off on Wall Street shows no signs of easing as coronavirus continues to spread worldwide. US500 (S&P 500 futures underlying) is closing in on a key technical hurdle - 200-session moving average (purple line). This one of the most often respected moving average by the market and was tested a dozen times over the past few years. The question remains whether it will manage to fend off the bears this time as well or is US500 set for a break lower? In case of a break lower major support can be found at 2940 pts. Source: xStation5
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appBest Buy (BBY.US) released earnings report for fiscal Q4 2020 (ended February 1 2019). The company generated quarterly revenue of $15.20 billion against expected $15.05 billion. Adjusted EPS of $2.90 was 6.6% higher year-over-year and 6.2% higher than expected. International revenue stood at $1.35 billion and grew 3.4% YoY. The company expects Q1 2021 (February-April period) to fall in the $9.1-9.2 billion range while EPS should come in between $1.00 and $1.05. Quarterly dividend was boosted by 10% to $0.55 per share. Company said that it closely monitors coronavirus developments but is unable to determine the exact financial impact of supply chain disruptions.
Gilead Science (GILD.US) said it is starting two Phase 3 trials of its Remdesivir drug. The World Health Organization said that this drug may be the only one to show efficacy. One trial will be conducted on 400 patients with severe clinical manifestation of coronavirus while the other will be conducted on 600 patients with mild manifestation. Trials will start in March.
Gilead Science (GILD.US) is trading over 5% higher in premarket. The company is enjoying a strong run higher as investors hope its new drug will show effects in fighting coronavirus. The stock is set to launch today’s session near $79 handle. Note that this level met with price reaction a few times therefore bulls may find it hard to crack. Source: xStation5
Microsoft (MSFT.US) issued a sales warning related to coronavirus. The US tech company said that it is likely to miss the previously issued forecast for fiscal Q3 2020 (calendar Q1 2020) for the personal computing segment. Forecast pointed at revenue coming in between $10.75 and $11.75 billion. The company still expects cloud revenue to fall in the $11.85-12.05 billion range. The company said that while demand for its PC products remains solid, supply chain disruptions are taking longer to abate. The warning came a few days after Apple (AAPL.US) said that the health crisis is likely to have a negative impact on its revenue in the quarter.
Uber Technologies (UBER.US) is trading lower in premarket. The situation is said to be an aftermath of Margrethe Vestager’s interview with Bloomberg. Vestager, who serves as EU Competition Commissioner, said that she is looking for ways to boost wages for employees of online food delivery companies or drivers of ride-hailing companies.
Share price of Uber Technologies (UBER.US) dropped over 15% this week and reached the support zone ranging above the 50% Fibo level of the upward move started in November 2019. The company is trading lower in premarket following Vestager’s interview with Bloomberg. Stock is set to open near the 61.8% Fibo level ($31.75 area). Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
